Nefazodone Hcl (Nefazodone Hcl)
Overview of Nefazodone Hcl
Nefazodone Hcl is a phenylpiperazine antidepressant structurally similar to trazodone, but nefazodone causes less sedation or orthostatic hypotension. Nefazodone is one of a new oral antidepressant with a mechanism of action distinct from other antidepressants. It blocks the reuptake of serotonin at presynaptic neurones and is an antagonist at post-synaptic 5-HT 2 receptors. It also inhibits reuptake of nor-adrenaline and blocks alpha-1 adrenoceptor but has no appearent effect on dopamine receptors. Nefazodone Hcl is as effective as other antidepressants in treating major depression but lacks cardiovascular toxicity seen with tricyclics and does not cause restlessness or insomnia frequently associated with the selective serotonin reuptake inhibitors (SSRIs). Nefazodone was FDA approved in December 1994 for treatment of major depression.
Indication of Nefazodone Hcl
Nefazodone Hcl is primarily indicated in conditions like Depression, Depressive illness.
Contraindication of Nefazodone Hcl
Nefazodone (HCl) is contraindicated in conditions like Hypersensitivity,Lactation.
Side Effects of Nefazodone Hcl
The severe or irreversible adverse effects of Nefazodone (HCl), which give rise to further complications include Hypomania, Serotonin syndrome.,The signs and symptoms that are produced after the acute overdosage of Nefazodone (HCl) include Sinus bradycardia, Nausea & vomiting, Somnolence, Decreased systolic pressure.,The symptomatic adverse reactions produced by Nefazodone (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Fever, Constipation, Dry mouth, Blurred vision, Chills, Somnolence, Postural hypotension, Light headedness, Dry mouth, dizziness.
Precautions of Nefazodone Hcl
It should be used cautiously in patients with epilepys, a history of hypomania or mania, severe renal or hepatic impairment, and those with arecent history of myocardial infarction or unstable heart disease. It should be used with caution in cardiovascular or cerebrovascular diseases that could be exacerbated with hypotension, and in any condition such as dehydration or hypovolumia that may predispose patient to hypotension. Patients should not derived or operate machinary. The dose may be increased gradually. Elderly patients, especially females may have higher plasma concentration than other patients. Doses should be restricted to lower end of the range in patients with hepatic or severe renal impairment. Patient should be closely monitored during early antiderpressant therapy until improvement in depression is observed because suiside is an inherent risk in depressed pateints. It should be withdrawn gradually to reduce the risk of withdrawal symptoms.